Guest J F, Ayoub N, Greaves T
Director of Catalyst, Visiting Professor of Health Economics, Researcher Assistant, Catalyst Health Economics Consultants, Northwood, Middlesex, UK.
Director of Catalyst, Visiting Professor of Health Economics, Faculty of Life Sciences and Medicine, King's College, London, UK.
J Wound Care. 2015 Dec;24(12):572, 574-80. doi: 10.12968/jowc.2015.24.12.572.
To estimate the cost-effectiveness of treating patients with a venous leg ulcer (VLU) with an externally applied electroceutical (EAE) device, plus dressings and compression bandaging or continuing with their previous care plan, from the perspective of the National Health Service (NHS) in the UK.
This was a prospective, single-arm, non-blinded, clinical and economic evaluation of EAE therapy performed in 2013/14. Patients' VLUs were treated with six active units of EAE therapy (each unit for two days) plus dressings and compression bandaging over a period of 12 days. Afterwards, patients were managed with a combination of dressings and bandages. Each patient acted as their own control so that clinical outcomes, resource use and costs associated with the wound over 12 months before the start of EAE therapy were retrospectively compared with the first 12 months after the start of treatment. The relative cost-effectiveness of EAE therapy was estimated at 2013/14 prices.
Within 12 months of starting EAE therapy 77% of all wounds healed and the other 23% improved. This difference in effectiveness between the 12-months period before and after EAE therapy was estimated to yield a 12% improvement in health gain of 0.09 QALYs (p<0.01), a 34% reduction in the requirement for nurse visits (from a mean 50.7 to 33.3 visits per patient) and a 26% reduction in the number of dressings. This resulted in an 11% reduction in the NHS cost of VLU management over 12 months after the start of treatment when compared with the previous 12 months (from £1,981 to £1,754 per patient). Hence, use of EAE therapy was found to be a dominant treatment (i.e. improved outcome for less cost).
Within the study's limitations, use of the EAE device potentially affords the NHS a cost-effective treatment for managing VLUs when compared with patients remaining on their previous care plan.
从英国国家医疗服务体系(NHS)的角度,评估使用外用电子治疗(EAE)设备、敷料和加压绷带治疗下肢静脉溃疡(VLU)患者,与继续采用其先前护理方案相比的成本效益。
这是一项于2013/14年进行的EAE治疗的前瞻性、单臂、非盲法临床和经济评估。患者的VLU接受六个活性单位的EAE治疗(每个单位治疗两天),并在12天内使用敷料和加压绷带。之后,患者采用敷料和绷带联合治疗。每位患者自身作为对照,以便将EAE治疗开始前12个月内与伤口相关的临床结果、资源使用和成本,与治疗开始后的前12个月进行回顾性比较。EAE治疗的相对成本效益按2013/14年的价格估算。
在开始EAE治疗的12个月内,所有伤口的77%愈合,另外23%有所改善。据估计,EAE治疗前后12个月的疗效差异使健康收益提高了12%,即0.09个质量调整生命年(QALYs)(p<0.01),护士探访需求减少了34%(从每位患者平均50.7次降至33.3次),敷料使用数量减少了26%。与前12个月相比,这使得治疗开始后12个月内NHS管理VLU的成本降低了11%(从每位患者1981英镑降至1754英镑)。因此,发现使用EAE治疗是一种占优治疗(即成本更低且结果改善)。
在研究的局限性范围内,与继续采用先前护理方案的患者相比,使用EAE设备可能为NHS提供一种具有成本效益的VLU管理治疗方法。